Bristol-Myers & Queensland Medical Research Institute: Cancer Immunology "Strong Combination"
September 01, 2015 Source: Health
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];Currently, the PD-1/PD-L1 immunization competition is being staged fiercely. The best in this field, Bristol-Myers Squibb, Merck, Roche and AstraZeneca, are rapidly advancing their clinical programs for PD-1 or PD-L1 immunotherapy. The maximum clinical potential of single-agent and multiple combination therapies is investigated in a wide range of cancers.
Recently, the absolute leader in the field, Bristol-Myers Squibb, announced that it has signed a research cooperation and licensing agreement with the Queensland Medical Research Institute (QIMR) Berghofer Medical Research Institute to discover and develop new ones. Therapeutic antibodies are used in an undisclosed tumor immunology (IO) target. The cooperation also marks the latest investment in Bristol-Myers's continued investment in strategic partnerships and the acceleration of discovery and development of new immunotherapies through innovative technologies.
Bristol-Myers Squibb said the collaboration will bring significant experience and expertise to the company's innovative research in the field of immuno-oncology. Bristol-Myers is solely responsible for the clinical development and commercialization of the therapeutic antibodies found in this collaboration. The financial terms of the partnership have not been disclosed.
In the past few decades, surgery, radiation therapy, cytotoxicity or targeted therapy have become the mainstay of cancer clinical treatment, but for many advanced cancer patients, there has been a huge long-term survival and positive quality of life. Medical challenge.
In order to address these unmet medical needs, Bristol-Myers Squibb has been conducting innovative research in the field of immuno-oncology. Currently, the company is exploring a variety of compounds and immunotherapeutics for the treatment of different types of cancer, including the study of combination therapies for immuno-oncology agents that target different pathways of cancer treatment. Bristol-Myers Squibb is committed to advancing scientific research in the field of immuno-oncology, with the ultimate goal of improving the survival expectations of cancer patients and changing their lifestyles.
The Queensland Institute of Medical Research (QIMR) Berghofer Medical Institute is the world's leading translational research organization, focusing on cancer, infectious diseases, mental health and a range of complex disorders. Through close collaboration with clinicians and other research institutions, the agency's goal is to develop new diagnostic methods, more effective treatments, and preventive methods to improve patient health.
We continually strive to maintain our unwavering reputation through our exceptional product quality and customer service. We not only offer a complete line of superior quality products, but also work with our customers to develop new formulas and address the burgeoning market. So, we get so many goods response from our global customers. Welcome your exlusive customization of OEM and ODM, we will grow together and create brillant with you.
Combo Detector,2 In 1 Combine Detector,Combo Smoke Co Alarm,Smoke Detector Carbon Monoxide Combo
Rictron Industrial Co., Ltd , https://www.szrictron.com